2001
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
Katsaros D, Yu H, Levesque M, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi M, Diamandi A, Gordini G, Diamandis E, Massobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal Of Cancer 2001, 37: 478-485. PMID: 11267857, DOI: 10.1016/s0959-8049(00)00423-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor Binding Protein 3Middle AgedNeoplasm ProteinsNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisRisk FactorsConceptsIGFBP-3 levelsInsulin-like growth factorLower IGFBP-3 levelsEpithelial ovarian carcinomaIGFBP-3Overall survivalPatient survivalOvarian carcinomaGrowth factorUnfavourable prognostic featuresIGFBP-3 concentrationsClinico-pathological featuresEpithelial ovarian cancerPatients' overall survivalResponse of patientsOvarian cancer progressionAnti-apoptotic actionClinicopathological featuresPathological variablesPrognostic featuresResidual tumorDisease progressionOvarian cancerDisease prognosisAverage age
1997
Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseSurgical marginsClinicopathological featuresRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesSubset of patientsUnivariate logistic regression modelYear of surgeryLength of followupConventional prostate specific antigenDetection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918.. DOI: 10.1097/00005392-199703000-00047.Peer-Reviewed Original ResearchProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseMicro g.Clinicopathological featuresSurgical marginsRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesUnivariate logistic regression modelYear of surgerySubset of patientsLength of followup